Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
15.30
-0.66 (-4.14%)
At close: Oct 13, 2026, 4:00 PM EDT
15.30
0.00 (0.00%)
After-hours: Oct 13, 2026, 4:27 PM EDT

Company Description

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Dyne Therapeutics, Inc.
Dyne Therapeutics logo
CountryUnited States
Founded1984
IPO DateSep 17, 2020
IndustryBiotechnology
SectorHealthcare
Employees289
CEOJohn Cox

Contact Details

Address:
1560 Trapelo Road
Waltham, Massachusetts 02451
United States
Phone781 786 8230
Websitedyne-tx.com

Stock Details

Ticker SymbolDYN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$19.00
CIK Code0001818794
CUSIP Number26818M108
ISIN NumberUS26818M1080
Employer ID36-4883909
SIC Code2834

Key Executives

NamePosition
John G. Cox M.B.A.Chief Executive Officer, President and Director
Erick J. Lucera C.F.A., CPAChief Financial Officer, Principal Financial Officer and Principal Accounting Officer and Treasurer
Dr. Oxana Beskrovnaya Ph.D.Chief Innovation Officer
Johanna Friedl-NadererChief Commercial Officer
Dr. Douglas Kerr M.B.A., M.D., Ph.D.Chief Medical Officer
Dr. Axel WiestSenior Vice President and Head of Portfolio Strategy and Operations
Dr. Rajesh Manchanda Ph.D.Chief Technical Officer
James P. Bilotta M.B.A.Chief Digital and Information Officer
Alessandro MartuscelliChief Legal Officer
Lucia CelonaChief Human Resource Officer

Latest SEC Filings

DateTypeTitle
Sep 29, 20268-KCurrent Report
Sep 8, 2026144Filing
Sep 8, 2026144Filing
Sep 4, 2026144Filing
Aug 14, 2026144Filing
Aug 14, 2026144Filing
Aug 14, 2026144Filing
Aug 13, 2026144Filing
Aug 13, 2026144Filing
Aug 13, 2026144Filing